RESEARCH ARTICLE
Docking Studies of Methylthiomorpholin Phenols (LQM300 Series) with Angiotensin-Converting Enzyme (ACE)
Víctor H Vázquez-Valadez*, V.H Abrego, Pablo A Martínez, Gabriela Torres, Oscar Zúñiga, Daniel Escutia, Rebeca Vilchis, Ana Ma. Velázquez, Luisa Martínez, Mónica Ruiz, Brígida Camacho, Rafael López-Castañares, Enrique Angeles
Article Information
Identifiers and Pagination:
Year: 2013Volume: 7
First Page: 30
Last Page: 38
Publisher ID: TOMCJ-7-30
DOI: 10.2174/1874104501307010030
Article History:
Received Date: 13/8/2013Revision Received Date: 26/9/2013
Acceptance Date: 11/10/2013
Electronic publication date: 23/11/2013
Collection year: 2013
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Abstract
A main target in the treatment of hypertension is the angiotensin-converting enzyme (ACE). This enzyme is responsible for producing angiotensin II, a potent vasoconstrictor. Therefore, one of the targets in the treatment of hypertension is to inhibit ACE activity. Hence, this study’s aim is to use computational studies to demonstrate that the proposed heterocyclic compounds have a molecular affinity for ACE and that, furthermore, these heterocyclic compounds are capable of inhibiting ACE activity, thus avoiding the production of the vasopressor Angiotensin II. All this using computer-aided drug design, and studying the systems, with the proposed compounds, through molecular recognition process and compared with the compounds already on the market for hypertension.
